Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
J Clin Microbiol ; 59(3)2021 02 18.
Article in English | MEDLINE | ID: mdl-33303562

ABSTRACT

As the coronavirus disease 2019 (COVID-19) pandemic second wave is emerging, it is of the upmost importance to screen the population immunity in order to keep track of infected individuals. Consequently, immunoassays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high specificity and positive predictive values are needed to obtain an accurate epidemiological picture. As more data accumulate about the immune responses and the kinetics of neutralizing-antibody (nAb) production in SARS-CoV-2-infected individuals, new applications are forecast for serological assays such as nAb activity prediction in convalescent-phase plasma from recovered patients. This multicenter study, involving six hospital centers, determined the baseline clinical performances, reproducibility, and nAb level correlations of 10 commercially available immunoassays. In addition, three lateral-flow chromatography assays were evaluated, as these devices can be used in logistically challenged areas. All assays were evaluated using the same patient panels in duplicate, thus enabling accurate comparison of the tests. Seven immunoassays examined in this study were shown to have excellent specificity (98 to 100%) and good to excellent positive predictive values (82 to 100%) when used in a low (5%)-seroprevalence setting. We observed sensitivities as low as 74% and as high as 95% at ≥15 days after symptom onset. The determination of optimized cutoff values through receiver operating characteristic (ROC) curve analyses had a significant impact on the diagnostic resolution of several enzyme immunoassays by increasing the sensitivity significantly without a large trade-off in specificity. We found that spike-based immunoassays seem to be better correlates of nAb activity. Finally, the results reported here will add to the general knowledge of the interlaboratory reproducibility of clinical performance parameters of immunoassays and provide new evidence about nAb activity prediction.


Subject(s)
Antibodies, Neutralizing/analysis , Antibodies, Viral/analysis , COVID-19/diagnosis , High-Throughput Screening Assays/standards , COVID-19/immunology , Humans , Laboratories , Reproducibility of Results , SARS-CoV-2 , Sensitivity and Specificity , Seroepidemiologic Studies
2.
J Eur Acad Dermatol Venereol ; 35(4): 787-796, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33090558

ABSTRACT

Atopic dermatitis (AD) is a disease that can have a high impact on quality of life, especially due to itch and skin pain. This paper utilizes expertise from members of the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force to review the epidemiology, pathophysiology and exacerbating factors of itch and pain in atopic dermatitis. General principles of treatment are provided, as well as a more detailed evaluation of topical and systemic therapies. Educational and psychological approaches to itch and pain in atopic dermatitis are proposed, along with expert recommendations for the management of itch and pain in atopic dermatitis.


Subject(s)
Dermatitis, Atopic , Dermatology , Dermatitis, Atopic/complications , Dermatitis, Atopic/therapy , Humans , Pain , Pruritus/etiology , Pruritus/therapy , Quality of Life
3.
J Eur Acad Dermatol Venereol ; 34(5): 1098-1104, 2020 May.
Article in English | MEDLINE | ID: mdl-31721327

ABSTRACT

BACKGROUND: Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical formulations containing corticosteroids and/or vitamin D3 analogs are recommended for treatment. OBJECTIVE: This phase II study aimed to evaluate the safety, including any potential effect on the hypothalamic-pituitary-adrenal axis and calcium metabolism, and efficacy of fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) (Cal/BD) gel in adolescents with psoriasis. METHODS: Patients aged 12 to <17 years, with at least mild psoriasis on the body and scalp, received topical Cal/BD gel once daily for ≤8 weeks. Safety response criteria included adverse drug reactions [ADRs; any adverse event (AE) possibly or probably related to treatment as determined by the investigator; a primary response criterion] and AEs (a secondary response criterion). Only treatment-emergent AEs (events that occurred after the first application of Cal/BD gel or events which started before this and increased in intensity after the first application of Cal/BD gel) are presented here. Efficacy response criteria included controlled disease, by physician's global assessment of disease severity (PGA), following Cal/BD gel treatment. RESULTS: A total of 107 patients (median age 14 years; range 12-16) were enrolled and treated. Eight ADRs were observed in 7 (7%) patients and 38 (36%) patients experienced ≥1 AE. The most common AEs were headache [6 (6%) patients], nasopharyngitis [6 (6%) patients] and blood parathyroid hormone increased [4 (4%) patients]. One severe AE was reported (attempted suicide) but was considered unrelated to treatment. At the end of treatment, 58% of patients had controlled disease on the body and 69% on the scalp according to PGA. CONCLUSION: In this uncontrolled phase II study, Cal/BD gel was well tolerated and effective for treating scalp and body psoriasis in adolescents.


Subject(s)
Dermatologic Agents , Psoriasis , Adolescent , Betamethasone/adverse effects , Calcitriol/analogs & derivatives , Child , Dermatologic Agents/adverse effects , Drug Combinations , Humans , Hypothalamo-Hypophyseal System , Pituitary-Adrenal System , Psoriasis/drug therapy , Scalp , Treatment Outcome
4.
Br J Dermatol ; 181(6): 1177-1189, 2019 12.
Article in English | MEDLINE | ID: mdl-31017657

ABSTRACT

BACKGROUND: Adalimumab (ADA) (Humira® , AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis. OBJECTIVES: To evaluate the long-term efficacy and safety of ADA in children with severe plaque psoriasis. METHODS: Results are presented from the 52-week long-term extension (LTE) of the randomized, double-blind, double-dummy, phase III trial, in children with severe plaque psoriasis (results from prior periods have been published). Patients aged ≥ 4 and < 18 years were randomized 1 : 1 : 1 to ADA 0·8 mg kg-1 (40 mg maximum) or 0·4 mg kg-1 (20 mg maximum) every other week or to methotrexate (MTX) 0·1-0·4 mg kg-1 (25 mg maximum) weekly. The 16-week initial treatment (IT) period was followed by a 36-week withdrawal period and a 16-week retreatment period. Patients could enter the LTE at prespecified time points to receive ADA 0·8 mg kg-1 (blinded or open label) or ADA 0·4 mg kg-1 (blinded), or to remain off treatment. Efficacy is reported for patient groups according to doses received in the IT and LTE periods. RESULTS: Of the 114 patients randomized in the IT period, 108 entered the LTE (n = 36 in each group); 93 received ADA 0·8 mg kg-1 . Efficacy (≥ 75% improvement from baseline in Psoriasis Area and Severity Index) was maintained or improved from entry to the end of the LTE: MTX(IT)/ADA 0·8(LTE) 31-86% of patients; ADA 0·4(IT)/0·4 or 0·8(LTE) 28-47%; ADA 0·8(IT)/0·8(LTE) 50-72%. No serious infections occurred in the LTE. CONCLUSIONS: After 52 weeks of long-term ADA treatment in children aged 4-18 years with severe plaque psoriasis, disease severity was reduced and maintained or further improved, as demonstrated by efficacy outcomes. No new safety risks were identified. What's already known about this topic? The results from the first three periods of this phase III trial in children aged 4-18 years with severe plaque psoriasis suggest that adalimumab is a safe and efficacious treatment option in this population. What does this study add? This is the first study to evaluate long-term treatment of adalimumab in children with severe psoriasis, and the first to evaluate switching from methotrexate to adalimumab in this population.


Subject(s)
Adalimumab/administration & dosage , Biological Factors/administration & dosage , Methotrexate/administration & dosage , Psoriasis/drug therapy , Severity of Illness Index , Adalimumab/adverse effects , Adolescent , Biological Factors/adverse effects , Child , Child, Preschool , Chronic Disease/drug therapy , Double-Blind Method , Female , Humans , Long-Term Care/methods , Male , Methotrexate/adverse effects , Psoriasis/diagnosis , Psoriasis/immunology , Time Factors , Treatment Outcome
5.
Allergy ; 72(11): 1713-1719, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28439896

ABSTRACT

BACKGROUND: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. METHODS: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. RESULTS: A total of 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear, and 79% reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7%±20.5. Mean TOPICOP subscores were 37.0±22.8% for knowledge and beliefs, 54.7±27.8% for fears and 50.1±29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. CONCLUSIONS: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Dermatitis, Atopic/drug therapy , Phobic Disorders , Administration, Topical , Child , Child, Preschool , Dermatitis, Atopic/psychology , Feasibility Studies , Humans , Infant , Prospective Studies , Surveys and Questionnaires
6.
Br J Dermatol ; 169(6): 1265-71, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24032480

ABSTRACT

BACKGROUND: Linear morphoea (LM) is a rare fibrosing disorder of the limbs or the face that may cause functional disability and severe aesthetic sequelae. Despite a wide range of therapeutics reported for LM, there is currently a lack of consensus on the optimal therapy. Little is known about the long-term outcome of this disease. OBJECTIVES: To describe the short- and long-term outcome of a large series of patients with LM acquired in childhood. METHODS: A retrospective chart review of 52 paediatric patients with LM seen in our centre during a 20-year span (1990-2010) and a telephone survey in 2011 to assess the long-term outcome of these patients. RESULTS: Limbs were affected twice as often as the face, with a higher proportion of female patients. Stabilization was obtained after a mean disease duration of 5·4 years. Patients sometimes experienced long stretches of disease quiescence followed by reactivation; 31% of patients reported active disease after 10 years. All but one patient had aesthetic sequelae, and 38% had functional limitations. The effectiveness of methotrexate and systemic corticosteroids was apparent in the short term. CONCLUSIONS: LM needs prolonged monitoring as the disease can have very long periods of quiescence followed by reactivation. The combination of methotrexate and systemic corticosteroids was effective in the early stages of the disease but did not seem to prevent long-standing active disease or relapse in the long term.


Subject(s)
Dermatologic Agents/therapeutic use , Scleroderma, Localized/therapy , Adolescent , Adrenal Cortex Hormones/therapeutic use , Age of Onset , Aminoquinolines/therapeutic use , Calcitriol/analogs & derivatives , Calcitriol/therapeutic use , Child , Drug Therapy, Combination , Female , Humans , Imiquimod , Male , Methotrexate/therapeutic use , Ointments , Phototherapy/methods , Retrospective Studies , Scleroderma, Localized/pathology , Tacrolimus/therapeutic use , Treatment Outcome , Vitamin A/therapeutic use , Vitamin E/therapeutic use
7.
Dermatol Clin ; 18(4): 667-73, ix, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11059375

ABSTRACT

Appearance in adolescents is a means of communication, a language expressing self identity. Teenagers explore fashions to make personal statements. Teenagers are significant consumers of various toiletry and skin care products that fill their cleansing, hydrating, and photoprotective needs. They also are enthusiastic consumers of products aimed at adolescent fads, such as decorative hair and nail cosmetics. For some teenagers, the expression of individualism is achieved through body art, such as tattooing and body piercing. Areas of concern are the lack of motivation for sun protection and the risky behavior associated with body piercing and tattooing.


Subject(s)
Body Image , Cosmetics/therapeutic use , Punctures , Tattooing , Adolescent , Cosmetics/adverse effects , Demography , Dermatitis, Allergic Contact/etiology , Female , Hair Preparations/adverse effects , Humans , Male , Product Labeling , Punctures/adverse effects , Tattooing/adverse effects
8.
J Am Acad Dermatol ; 43(3): 540-6, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10954672

ABSTRACT

A 15-year-old boy experienced a macular serpentine erythematous eruption that subsided with a persistent hyperpigmentation overlying the superficial venous network of the left forearm. This reaction occurred at the injection site of a chemotherapy regimen that combined actinomycin and vincristine a few hours after the first course. After a single injection of actinomycin in the right arm, a similar reaction occurred, implicating it as the responsible agent. A skin biopsy specimen demonstrated a cell-poor interface tissue reaction associated with an eccrine neutrophilic hidradenitis. To our knowledge, this is the first case of persistent supravenous serpentine hyperpigmented eruption reported in a child treated with this particular drug combination.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Drug Eruptions/pathology , Hyperpigmentation/chemically induced , Adolescent , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Arm/pathology , Dactinomycin/administration & dosage , Dactinomycin/adverse effects , Humans , Male , Vincristine/administration & dosage , Vincristine/adverse effects
9.
Semin Cutan Med Surg ; 18(3): 244-9, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10468044

ABSTRACT

Adolescence is a period of tremendous transformation in the appearance of the body and the evolution of the mind that will eventually lead to adulthood. "Yesterday's child" will need to assume and exert control over these changes. Therefore his/her appearance becomes a means of communication, a language to express his/her pursuit of self-identity. The cosmetic industry has identified teenagers as "powerful" consumers, and offers them various toiletry and skin care products that should fulfill their needs, such as cleansing, hydrating, and photoprotective agents. Certain decorative cosmetics, especially for hair and nails, are attractive to them also. For some teenagers, the expression of individualism is through body art such as tattooing and body piercing. Areas of concern are the lack of motivation for sun protection and the risky behavior associated with body piercing and tattooing.


Subject(s)
Body Image , Cosmetics , Psychology, Adolescent/trends , Skin Diseases/psychology , Adolescent , Cosmetics/adverse effects , Female , Humans , Male , Punctures/psychology , Self Medication , Tattooing/adverse effects
11.
J Am Acad Dermatol ; 36(2 Pt 1): 203-8, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9039169

ABSTRACT

BACKGROUND: The use of topical calcipotriol in adults with psoriasis is safe and effective. OBJECTIVE: Our purpose was to study the efficacy and safety of calcipotriol in children. METHODS: A multicenter, prospective, 8-week, double-blind, parallel group study was conducted in 77 children. Response to treatment was assessed by means of the Psoriasis Area and Severity Index (PASI) in that the intensity of redness, thickness, and scaliness as well as the area involved are scored. The children were 2 to 14 years of age and had stable psoriasis, involving less than 30% of the body surface. Forty-three children were assigned to receive calcipotriol ointment and 34 to receive placebo. Nine children dropped out of the study, six in the calcipotriol-treated group and three in the placebo-treated group. RESULTS: Both treatment groups (calcipotriol and placebo) showed significant improvement in PASI from baseline to the end of treatment, and the difference was not statistically significant. No serious side effects, in particular including those relating to calcium and bone metabolism, were recorded. CONCLUSION: Calcipotriol ointment was statistically significantly more effective than its vehicle in terms of the investigator's overall assessment and reduction in redness and scaliness but not in terms of PASI score.


Subject(s)
Calcitriol/analogs & derivatives , Dermatologic Agents/administration & dosage , Psoriasis/drug therapy , Administration, Topical , Adolescent , Analysis of Variance , Biomarkers/blood , Calcitriol/administration & dosage , Calcitriol/adverse effects , Child , Child, Preschool , Dermatologic Agents/adverse effects , Double-Blind Method , Female , Humans , Male , Patient Compliance , Peptide Fragments/blood , Procollagen/blood , Prospective Studies , Psoriasis/blood
12.
J Am Acad Dermatol ; 34(6): 979-84, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8647991

ABSTRACT

BACKGROUND: Four years ago, we began seeing young children with an unusual, predominantly unilateral, morbilliform and eczematous, self-limited cutaneous eruption. It appeared to correspond to unilateral laterothoracic exanthem (ULE) reported from France and to an eruption described as "a new papular erythema of childhood" in the United States. OBJECTIVE: We conducted a prospective study of ULE to define its clinical evolution, pathology, and therapy. In addition, we performed epidemiologic and microbiologic investigations in an attempt to determine the cause of ULE. METHOD: We studied 48 children with ULE. In some patients, blood, urine, stool, as well as skin biopsy specimens were analyzed. RESULTS: ULE is a morbilliform, eczematous eruption that often begins close to the axilla and spreads to become bilateral, although it usually retains a unilateral predominance. Patients' mean age at onset is 24.3 months, with a female predominance (2:1) and mean duration of 5 weeks, followed by spontaneous resolution that may or may not be improved with topical corticosteroids. It is characterized by a unique eccrine lymphocytic infiltration. Although signs of infection were reported by most patients, no one infectious agent was identified. No significant epidemiologic factor was found. CONCLUSION: ULE, in young children, is a self-limited morbilliform and scarlatiniform eruption that may represent a specific skin reaction to one or more infectious agents.


Subject(s)
Exanthema/pathology , Administration, Topical , Anti-Inflammatory Agents/therapeutic use , Axilla , Biopsy , Child, Preschool , Dermatologic Agents/therapeutic use , Eccrine Glands/pathology , Eczema/drug therapy , Eczema/microbiology , Eczema/pathology , Erythema/drug therapy , Erythema/microbiology , Erythema/pathology , Exanthema/drug therapy , Exanthema/physiopathology , Female , Glucocorticoids , Humans , Infant , Lymphocytes/pathology , Male , Prospective Studies , Quebec , Remission, Spontaneous , Sex Factors , Skin/pathology , Thorax
14.
J Am Acad Dermatol ; 28(5 Pt 2): 820-6, 1993 May.
Article in English | MEDLINE | ID: mdl-8491872

ABSTRACT

Three new unrelated cases of PIBIDS (Photosensitivity, Ichthyosis, Brittle, sulfur-deficient hair [trichothiodystrophy], Impaired intelligence, Decreased fertility, and Short stature) are reported. Decreased survival of skin fibroblast lines after UVB exposure was found. All three male patients had hypogonadism and primary end-organ gonadal failure. Striking osteosclerosis was present in all three patients. To the best of our knowledge the third patient is the first reported case of a black man with PIBIDS.


Subject(s)
Hair/abnormalities , Hypogonadism , Osteosclerosis , Photosensitivity Disorders , Sulfur/deficiency , Adult , Age Determination by Skeleton , Body Height , Child, Preschool , Face , Humans , Hypogonadism/pathology , Ichthyosis/pathology , Intellectual Disability , Male , Osteosclerosis/pathology , Photosensitivity Disorders/pathology , Sexual Maturation , Syndrome
15.
Pediatr Dermatol ; 8(3): 189-93, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1745626

ABSTRACT

Four children under 2 years of age were treated at our hospital in the last three years with a recurrent vesiculopustular eruption of the scalp, variably extending to the face and limbs. All cases followed a cyclical pattern. Three of the children had a moderate response to topical steroids, and one went into remission after a two-month course of erythromycin. Ethnic origin may be an important predisposing factor. Histologically, all patients showed a moderate mixed inflammatory infiltrate with numerous eosinophils centered around hair follicles. Peripheral white blood cell count showing leukocytosis with eosinophilia was observed in those cases measured, but no consistent immunologic abnormalities could be identified.


Subject(s)
Eosinophilia , Folliculitis , Eosinophilia/diagnosis , Eosinophilia/drug therapy , Folliculitis/diagnosis , Folliculitis/drug therapy , Humans , Infant , Infant, Newborn , Male , Steroids/therapeutic use
16.
Epidemiology ; 1(5): 377-81, 1990 Sep.
Article in English | MEDLINE | ID: mdl-2078613

ABSTRACT

Age at menarche shows a downward secular trend and differs according to socioeconomic conditions, presumably the result of dietary variations. We report two studies conducted in Quebec City in which the relation between diet and menarche was evaluated. In 1978-1980, baseline information for these studies was obtained on girls aged 9 through 15 and included body weight, height, fatfold thickness at six sites, percent of body fat (derived from underwater weighing), and a 3-day dietary record. In a cross-sectional study of 207 girls aged 11 through 15, we compared dietary patterns between premenarcheal and menarcheal girls using logistic regression. In a 6-year follow-up study of 109 girls who had not experienced menarche at the baseline data collection, the relation between time of occurrence of menarche and dietary patterns was assessed using proportional hazards models. The results confirm the association between body weight and age at menarche. Body fat, however, was not strongly related to the onset of menstruation. In both studies, a higher dietary energy intake was associated with an earlier age at menarche. Dietary composition, and dietary fat in particular, was not related to menarche.


Subject(s)
Diet , Menarche , Adolescent , Body Mass Index , Body Weight , Child , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Quebec , Skinfold Thickness , Surveys and Questionnaires
18.
Am J Anat ; 177(3): 333-52, 1986 Nov.
Article in English | MEDLINE | ID: mdl-2432770

ABSTRACT

This work reconsiders aspects of the morphology of the capsule, of the blood vasculature, of the distribution of reticular fibers, and of the diffusion of intramediastinally injected antigens in the stroma of the thymus of the rat. This was done by an analysis of standard sections of normal thymuses, of sections of thymuses perfused with colloidal carbon, of silver-impregnated sections, and of sections of thymuses of rats injected intramediastinally with a fluorescent antigen or intravenously with Trypan blue, and by electron microscopy of the thymic capsule. The capsule consisted of two layers: an outer layer covering the entire periphery of a thymic lobe, and an inner layer which outlined the entire convoluted peripheral cortex of a lobe. Cortical vessels entered the capsule and septa in which they formed a capillary network. These capsular capillaries were fenestrated and leukocytes were often present near them. Adipocytes were also seen near these vessels in some areas of the capsule, and often at the bases of septa and trabeculae. Furthermore, much of the medulla had a dense network of coarse reticular fibers, whereas the remainder of the medulla and the cortex contained a loose network of fine fibers stretching out from the capsule, septa, and trabeculae. Intramediastinally injected fluorescent antigens were observed to spread in the capsule and septa and to diffuse in the fiber networks stretched across the cortex and the medulla. Fluorescence also highlighted cortical reticular cells but not the thymocytes. Intravenously injected Trypan blue stained the capsule, the septa, the cortical reticular cells, and the autofluorescent cells outlining the corticomedullary junction of each lobule. The unusual penetration of capillaries from the thymic parenchyma into the thymic capsule suggested that the capsular capillaries participate in peculiar thymic events, such as the recruitment of blood stem-cells. It is concluded that small amounts of blood antigens normally exude from capsular capillaries and diffuse into the fibers extending from the capsule across the cortex. The phenomenon would be increased under conditions causing thymic involution. An explanation is proposed to account for the development of involution which involves the exudation of antigens from the capsular capillaries. A comparable mechanism could also account for the development of a particular experimental immune tolerance.


Subject(s)
Antigens/immunology , Thymus Gland/anatomy & histology , Animals , Blood Vessels/anatomy & histology , Blood Vessels/ultrastructure , Diffusion , Injections , Injections, Intravenous , Mediastinum , Microscopy, Electron , Rats , Rats, Inbred Strains , Staining and Labeling , Thymus Gland/blood supply , Thymus Gland/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...